Sacituzumab govitecan: Additional Phase I/II data

Data from 56 evaluable patients with various types of gastrointestinal cancers in an open-label, U.S. Phase I/II trial showed that sacituzumab govitecan on days 1 and 8 of a 21-day cycle for up to 8 c...